Loading…
Employees: 1,605
Size Cheng Du Sheng Nuo Biotec (688117.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $496M, the 3886th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥15.01 on 6 Nov 2026.
Performance Over six months the shares fell 43.8%, against -16.4% for the median peer and -16.4% for the China market (cap-weighted) — 3rd lowest of 20 in its peer set.
Growth Revenue grew 50.8% over the last twelve months (peer median -0.4%); the operating margin is 27.5% (peer median -4.1%).
Valuation It trades at 14.3× forward earnings against a peer median of 14.1× (3rd cheapest of 5).
Price implies For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is +14%, so the hurdle is -13 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 8.2 points above its cost of capital (6.7% WACC).
Next results Next results expected around 27 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥963M | CN¥740M | CN¥454M | CN¥431M | CN¥391M |
| Revenue growth | — | +63% | +5% | +10% | — |
| Gross profit | CN¥585M | CN¥408M | CN¥251M | CN¥266M | CN¥248M |
| EBITDA | n/a | CN¥267M | CN¥101M | CN¥105M | CN¥90.1M |
| Net income | CN¥202M | CN¥158M | CN¥50.0M | CN¥70.3M | CN¥64.5M |
| Free cash flow | CN¥33.6M | CN¥33.2M | -CN¥219M | -CN¥191M | -CN¥35.8M |
| Capital expenditure | CN¥159M | CN¥146M | CN¥247M | CN¥278M | CN¥136M |
| Total debt | CN¥746M | CN¥612M | CN¥534M | CN¥267M | CN¥103M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688117.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -16.5% | -8.9% | 4th lowest of 21 |
| 6-month return | -43.8% | -16.4% | 3rd lowest of 20 |
| Distance from 52-week high | -54.8% | -38.8% | 2nd lowest of 21 |
| Revenue growth (TTM) | +50.8% | -0.4% | 2nd highest of 19 |
| Operating margin | 27.5% | -4.1% | highest of 19 |
| Forward P/E | 14.3× | 14.1× | 3rd cheapest of 5 |
| Growth the price implies (Req g, 7 yrs) | 1.7% | 6.2% | 4th least demanding of 9 |
| Growth delivered (Del g) | +14.5% | +0.9% | highest of 9 |
| Hurdle (Req g minus delivered) | -12.8 pp | +6.9 pp | 2nd least demanding of 9 |
| ROIC minus cost of capital | +8.2 pp | -5.4 pp | 2nd highest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Cheng Du Sheng Nuo Biotec 688117.SS | China | $496M | -44% | +51% | 27% | 14.3× | 1.7% | +14.5% |
| SMS Pharmaceuticals SMSPHARMA.NS | India | $495M | +18% | +10% | 15% | 44.1× | n/a | n/a |
| Shanghai MicuRx Pharmaceutical 688373.SS | China | $495M | -16% | +23% | -61% | n/a | n/a | n/a |
| Xiangxue Pharmaceutical 300147.SZ | China | $502M | -49% | +3% | -39% | n/a | 47.1% | -12.3% |
| Electra Therapeutics ETRA | United States | $490M | n/a | n/a | n/a | n/a | n/a | n/a |
| REGENXBIO RGNX | United States | $503M | -28% | +12% | -94% | n/a | n/a | n/a |
| PKU Healthcare 000788.SZ | China | $489M | -11% | -49% | 5% | n/a | -2.6% | -5.6% |
| Gyre Therapeutics GYRE | United States | $505M | -36% | +17% | -11% | n/a | n/a | n/a |
| Daewoong 003090.KS | South Korea | $485M | -29% | +5% | 11% | 4.1× | n/a | n/a |
| Tong Ren Tang Technologies 1666.HK | Hong Kong | $484M | -23% | -14% | 12% | 7.2× | -18.6% | +6.3% |
| Shanghai Shenqi Pharmaceutical Investment Management 600613.SS | China | $483M | +9% | -4% | 3% | n/a | 13.4% | +1.4% |
| Indaptus Therapeutics INDP | United States | $510M | +64% | n/a | n/a | n/a | n/a | n/a |
| Alpha Teknova TKNO | United States | $482M | +104% | +12% | -35% | n/a | n/a | n/a |
| Zhejiang Yatai Pharmaceutical 002370.SZ | China | $514M | -32% | -4% | -11% | n/a | n/a | n/a |
| CytomX Therapeutics CTMX | United States | $477M | -45% | -87% | -477% | n/a | n/a | n/a |
| Elixiron Immunotherapeutics (Cayman) 7871.TWO | Taiwan | $477M | +62% | +10,947% | -194% | n/a | n/a | n/a |
| Hainan Shuangcheng Pharmaceuticals 002693.SZ | China | $476M | -10% | +40% | 13% | n/a | 44.5% | +1.0% |
| Jiangsu Sihuan Bioengineering 000518.SZ | China | $476M | +7% | -17% | -28% | n/a | n/a | n/a |
| Pulike Biological Engineering 603566.SS | China | $475M | -22% | -9% | 5% | 21.0× | 5.7% | +3.3% |
| Shandong Wohua Pharmaceutical 002107.SZ | China | $519M | -18% | -4% | 18% | n/a | 6.7% | -4.1% |
| YungShin Global 3705.TW | Taiwan | $474M | +7% | -8% | 15% | n/a | -4.9% | +0.7% |